Form D · Other
HB Biotech, Inc.
New York, NY · CIK 0001958314
Offering snapshot reported Dec 15, 2022 · SEC filing
- Reported sold
- $7.8M Offering amount: $11M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 15, 2022 | Initial | $7,795,408 | No comparison | 17 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-467639
The issuer sold an aggregate of 58,467 shares of common stock at $133.33 per share to certain accredited investors.
Source: Form D, filed Dec 15, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Tomer Seifan | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
515 West 20 Th Street Suite 4 E
New York, NY, 10011
New York, NY, 10011